CMPX logo

CMPX
Compass Therapeutics Inc

744
Mkt Cap
$927.45M
Volume
5.58M
52W High
$6.88
52W Low
$1.33
PE Ratio
-11.88
CMPX Fundamentals
Price
$5.15
Prev Close
$5.39
Open
$5.40
50D MA
$5.90
Beta
1.58
Avg. Volume
2.01M
EPS (Annual)
-$0.4216
P/B
4.67
Rev/Employee
$0.00
$647.75
Loading...
Loading...
News
all
press releases
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, MarketBeat.com...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings
Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for Compass Therapeutics in a report issued on Thursday, March 5th. HC...
MarketBeat·13d ago
News Placeholder
What is HC Wainwright's Estimate for CMPX Q1 Earnings?
Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Compass Therapeutics in a research report...
MarketBeat·16d ago
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) released its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·16d ago
News Placeholder
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) DelveInsight
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...
PR Newswire·19d ago
News Placeholder
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX
Monashee Investment Management LLC grew its position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 657.6% in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·21d ago
News Placeholder
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the...
MarketBeat·29d ago
News Placeholder
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday
Compass Therapeutics (NASDAQ:CMPX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Compass Therapeutics (NASDAQ:CMPX) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Compass Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday...
MarketBeat·1mo ago
<
1
2
...
>

Latest CMPX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.